BAYRY
Bayer AG (ADR)

2,781
Mkt Cap
$53.05B
Volume
408,089.00
52W High
$13.98
52W Low
$5.30
PE Ratio
-155.53
BAYRY Fundamentals
Price
$13.56
Prev Close
$13.50
Open
$13.44
50D MA
$11.70
Beta
0.44
Avg. Volume
919,343.20
EPS (Annual)
-$0.7025
P/B
1.53
Rev/Employee
$543,158.75
$53,599.34
Loading...
Loading...
News
all
press releases
Will Eylea Sales Decline Weigh on REGN's Top Line in 2026?
Regeneron foresees further Eylea decline in 2026 as biosimilars loom, but Eylea HD, Dupixent and Libtayo aim to steady revenues.
Zacks·1d ago
News Placeholder
More News
News Placeholder
Why Bayer Aktiengesellschaft (BAYRY) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·2d ago
News Placeholder
Are You Looking for a Top Momentum Pick? Why Bayer Aktiengesellschaft (BAYRY) is a Great Choice
Does Bayer Aktiengesellschaft (BAYRY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·3d ago
News Placeholder
2 Intriguing Medical Stocks to Watch as Q4 Results Approach: EXEL, GILD
With their Q4 results approaching after-market hours on Tuesday, February 10, Exelixis (EXEL) and Gilead Sciences (GILD) are two top-performing medical stocks to consider.
Zacks·4d ago
News Placeholder
Here's Why Bayer Aktiengesellschaft (BAYRY) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·4d ago
News Placeholder
Bayer's Asundexian Shows 26% Stroke Reduction in Late-Stage Study
Bayer presents positive data on asundexian, which shows superior efficacy with no added bleeding risk, boosting hopes for regulatory approval.
Zacks·7d ago
News Placeholder
Are Medical Stocks Lagging Bayer (BAYRY) This Year?
Here is how Bayer Aktiengesellschaft (BAYRY) and Align Technology (ALGN) have performed compared to their sector so far this year.
Zacks·7d ago
News Placeholder
Lilly Stock Jumps After Q4 Earnings Beat and Strong 2026 Guidance
LLY beats Q4 earnings and sales estimates as Mounjaro and Zepbound surge. Shares jump on stronger-than-expected revenue and EPS outlook for 2026.
Zacks·9d ago
News Placeholder
Novartis Beats on Q4 Earnings, Entresto Generics Pressure Sales
NVS tops Q4 EPS estimates as margins expand, but revenues miss the mark amid U.S. generics hitting Entresto and Promacta, reshaping its growth mix.
Zacks·9d ago
News Placeholder
REGN Q4 Earnings Beat Estimates, Sales Rise on Eylea HD Growth
REGN beats Q4 earnings estimates as Eylea HD and Dupixent profits lift revenues, though higher expenses drive a year-over-year EPS decline.
Zacks·14d ago
<
1
2
...
>

Latest BAYRY News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.